Takeda (TAK) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Takeda, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track TAK live on Mooboard →

Next 30 days1

  • Oct 2, 2026
    Takeda(TAK)Phase 2/3 readout
    TAK-861 · Phase 3 · Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy
    NCT07363720: A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy. Primary completion 2026-10-02 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

31–90 days4

  • Oct 31, 2026
    Takeda(TAK)Phase 2/3 readout
    TAK-788 · Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
    NCT04129502: TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations. Primary completion 2026-10-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 31, 2026
    Takeda(TAK)Phase 2/3 readout
    TAK-788 · Phase 1 / Phase 2 · Carcinoma, Non-Small-Cell Lung
    NCT02716116: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer. Primary completion 2026-10-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 30, 2026
    Takeda(TAK)Phase 2/3 readout
    TAK-360 · Phase 2 · Narcolepsy Type 2
    NCT06952699: A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2). Primary completion 2026-11-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 30, 2026
    Takeda(TAK)Phase 2/3 readout
    TAK-360 · Phase 2 · Idiopathic Hypersomnia
    NCT06812078: A Study of TAK-360 in Adults With Idiopathic Hypersomnia. Primary completion 2026-11-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

Later20

  • Dec 31, 2026
    Takeda(TAK)Phase 2/3 readout
    Maribavir · Phase 3 · Cytomegalovirus (CMV)
    NCT06439342: A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections. Primary completion 2026-12-31 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 18, 2027
    Takeda(TAK)Phase 2/3 readout
    Maribavir · Phase 3 · Cytomegalovirus (CMV)
    NCT05319353: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT). Primary completion 2027-01-18 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 10, 2027
    Takeda(TAK)Phase 2/3 readout
    Teduglutide · Phase 3 · Short Bowel Syndrome
    NCT06973304: A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome. Primary completion 2027-02-10 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 17, 2027
    Takeda(TAK)Phase 2/3 readout
    TAK-279 · Phase 2 · Crohn's Disease
    NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease. Primary completion 2027-02-17 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 16, 2027
    Takeda(TAK)Phase 2/3 readout
    TAK-755 · Phase 3 · Thrombotic Thrombocytopenic Purpura (TTP)
    NCT04683003: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura. Primary completion 2027-03-16 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Apr 14, 2027
    Takeda(TAK)Phase 2/3 readout
    TDV · Phase 3 · Dengue Fever
    NCT06579755: A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years). Primary completion 2027-04-14 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • May 18, 2027
    Takeda(TAK)Phase 2/3 readout
    Zasocitinib · Phase 3 · Psoriatic Arthritis
    NCT06671496: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines. Primary completion 2027-05-18 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 18, 2027
    Takeda(TAK)Phase 2/3 readout
    Zasocitinib · Phase 3 · Psoriatic Arthritis
    NCT06671483: A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines. Primary completion 2027-05-18 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 30, 2027
    Takeda(TAK)Phase 2/3 readout
    Zasocitinib · Phase 3 · Palmoplantar Psoriasis
    NCT07752108: A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis. Primary completion 2027-05-30 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 8, 2027
    Takeda(TAK)Phase 2/3 readout
    Vedolizumab · Phase 3 · Crohn's Disease
    NCT06227910: A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease. Primary completion 2027-06-08 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 13, 2027
    Takeda(TAK)Phase 2/3 readout
    Vedolizumab IV · Phase 3 · Crohn's Disease (CD)
    NCT04779320: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD). Primary completion 2027-09-13 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 24, 2027
    Takeda(TAK)Phase 2/3 readout
    Vedolizumab IV · Phase 3 · Moderately to Severely Active Ulcerative Colitis
    NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis. Primary completion 2027-09-24 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 12, 2027
    Takeda(TAK)Phase 2/3 readout
    Zasocitinib · Phase 2 · Nonsegmental Vitiligo
    NCT07108283: A Study of Zasocitinib in Adults With Nonsegmental Vitiligo. Primary completion 2027-10-12 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 28, 2027
    Takeda(TAK)Phase 2/3 readout
    Rusfertide · Phase 2 · Polycythemia Vera
    NCT07648030: A Study of Rusfertide in Japanese Adults With Polycythemia Vera. Primary completion 2027-10-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 25, 2027
    Takeda(TAK)Phase 2/3 readout
    VONVENDI · Phase 3 · Von Willebrand Disease (VWD)
    NCT07129343: A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD). Primary completion 2027-11-25 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Nov 28, 2027
    Takeda(TAK)Phase 2/3 readout
    TAK-360 · Phase 2 · Narcolepsy Type 1
    NCT07633301: A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy). Primary completion 2027-11-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 2, 2027
    Takeda(TAK)Phase 2/3 readout
    TAK-411 · Phase 2 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    NCT06798012: A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Primary completion 2027-12-02 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 6, 2027
    Takeda(TAK)Phase 2/3 readout
    TAK-755 · Phase 2 · Acute Ischemic Stroke
    NCT07392450: A Study of TAK-755 in Adults With Acute Ischemic Stroke. Primary completion 2027-12-06 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 22, 2028
    Takeda(TAK)Phase 2/3 readout
    Zasocitinib (Dose A) · Phase 2 · Hidradenitis Suppurativa
    NCT07244263: A Study of Zasocitinib in Adults With Hidradenitis Suppurativa. Primary completion 2028-02-22 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Feb 28, 2028
    Takeda(TAK)Phase 2/3 readout
    TAK-861 · Phase 2 / Phase 3 · Narcolepsy Type 1
    NCT05816382: A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions. Primary completion 2028-02-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

How Takeda has moved — past-year price reactions

How binary is TAK? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

0.8%
typical day (1Y)
0
±10% days
21.1%
annualized vol
249
trading days
Largest single-day moves
  • +5.1%2026-07-02no matched headline
  • -4.8%2026-06-01no matched headline
  • -3.9%2025-10-30no matched headline
  • +3.9%2026-08-18no matched headline
  • +3%2026-01-08no matched headline
  • +2.9%2026-01-29no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Takeda — active clinical pipeline

Takeda's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

38 assets67 programsPh1 2Ph2 22Ph3 37· 6 post-marketing (Ph4)
AreasOncologyAutoimmuneImmunologyNeuroscienceCardiovascularRare / GeneticOther
ElriterceptOncology
Phase 2
Myelodysplastic SyndromesMyelofibrosis
Phase 3
Myelodysplastic SyndromeMyelodysplastic SyndromesMyelofibrosis
ZasocitinibAutoimmune
Phase 2
Crohn's Disease (2)Nonsegmental Vitiligo
Phase 3
Palmoplantar PsoriasisPlaque PsoriasisPsoriatic Arthritis (3)
TAK-360Neuroscience
Phase 2
Idiopathic HypersomniaNarcolepsy Type 1Narcolepsy Type 2
Phase 3
Idiopathic Hypersomnia
Vedolizumab IVAutoimmune
Phase 3
Crohn's DiseaseCrohn's Disease (CD)Moderately to Severely Active Ulcerative ColitisUlcerative Colitis (2)
MezagitamabAutoimmune · CD38
Phase 2
Antibody-Mediated Rejection (AMR)
Phase 3
Immune Thrombocytopenic Purpura (ITP) (2)Kidney Disease
TAK-279Autoimmune
Phase 2
Crohn's DiseaseUlcerative Colitis
Phase 3
Plaque Psoriasis
VedolizumabAutoimmune · ITGA4
Phase 3
Crohn's DiseasePouchitisUlcerative Colitis
TAK-755Cardiovascular · ADAMTS13
Phase 2
Acute Ischemic Stroke
Phase 3
Thrombotic Thrombocytopenic Purpura (TTP)
TAK-788Oncology · EGFR
Phase 2
Carcinoma, Non-Small-Cell Lung
Phase 3
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
TAK-861Neuroscience
Phase 3
Narcolepsy Type 1Narcolepsy Type 1 (NT1)
TAK-881Immunology
Phase 3
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Primary Immunodeficiency Diseases (PID)
Fazirsiran InjectionRare / Genetic
Phase 3
Alpha1-Antitrypsin Deficiency (3)
Idursulfase-ITOther
Phase 3
Hunter Syndrome
IGI, 10%Oncology
Phase 3
Multiple Myeloma
MaribavirOther · Serine/threonine-protein kinase BGLF4/UL97
Phase 3
Cytomegalovirus (CMV) (2)
PonatinibOncology
Phase 3
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
TAK-330Other
Phase 3
Coagulation Disorder
TAK-928Oncology
Phase 3
IO-resistant sqNSCLC
TDVOther
Phase 3
Dengue Fever (2)
TeduglutideOther · GLP2R
Phase 3
Short Bowel Syndrome
Tetravalent Dengue Vaccine (TDV)Other
Phase 3
Dengue Fever
Vedolizumab SCAutoimmune
Phase 3
Ulcerative Colitis
Vonicog AlfaOther · VWF
Phase 3
Von Willebrand Disease (VWD)
VONVENDIOther · VWF
Phase 3
Von Willebrand Disease (VWD)
Vortioxetine tabletsNeuroscience
Phase 3
Major Depressive Disorder
Brentuximab vedotinOncology · CD30 ADC
Phase 2
Hodgkin DiseaseLymphoma
RusfertideOther
Phase 2
Polycythemia Vera (2)
TAK-007Oncology
Phase 2
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
TAK-188Oncology
Phase 2
Advanced or Metastatic Solid Tumors
TAK-226Oncology
Phase 2
Myelodysplastic Syndromes
TAK-411Immunology
Phase 2
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
TAK-505Oncology
Phase 2
Malignant Solid Tumors
TAK-853Oncology
Phase 2
Ovarian Cancer
Zasocitinib (Dose A)Immunology
Phase 2
Hidradenitis Suppurativa
MobocertinibOncology · EGFR
Phase 1
Non-Small Cell Lung Cancer
TAK-781Other
Phase 1
Primary Sclerosing Cholangitis

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built

See the full biopharma catalyst calendar across all covered companies.